Background: Influenza vaccination is recommended especially for persons at risk of complications. In 2003, the World Health Assembly urged Member States (MS) to increase vaccination coverage to 75% among older persons by 2010. Objective: To assess progress towards the 2010 vaccination goal and describe seasonal influenza vaccination recommendations in the World Health Organization (WHO) European Region. Methods: Data on seasonal influenza vaccine recommendations, dose distribution, and target group coverage were obtained from two sources: European Union and European Economic Area MS data were extracted from influenza vaccination surveys covering seven seasons
Background
Seasonal influenza is an acute viral infection that occurs worldwide causing an estimated 3-5 million severe cases and up to 500 000 deaths every year [1] . Annual influenza epidemics in the northern hemisphere have been associated with increases in allcause mortality [2, 3] , significant economic costs due to lost workforce productivity and increased demand on outpatient and inpatient health care services [4] [5] [6] [7] [8] .
Influenza infection usually has a mild course, but can lead to severe disease and complications including acute myocardial infarction and cardiovascular death, primary viral and secondary bacterial pneumonia, renal failure, and neurological complications https://doi.org/10.1016/j.vaccine.2017.12.019 0264-410X/Ó 2017 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND IGO license. http://creativecommons.org/licenses/by-nc-nd/3.0/igo/ [9] [10] [11] . Particularly older people, pregnant women, infants, and persons with certain underlying comorbidities, including chronic cardiovascular and lung diseases, immunosuppression, and diabetes have a higher risk of hospitalization and severe disease, and are consequently priority groups for influenza vaccination [12] . Health care workers are also recommended to receive annual influenza vaccination due to a higher risk of infection and potential role in transmission of influenza to vulnerable patient groups [13] [14] [15] .
Influenza vaccination remains the most effective means to prevent infection, severe disease and mortality, why increasing seasonal influenza vaccine coverage has long been on the global health agenda. In 2003, the World Health Assembly (resolution WHA 56. 19 ) urged member states to increase influenza vaccination coverage of all people at high risk and to attain a coverage of 75% among older people and persons with chronic illnesses by 2010 [16] . This motion was reaffirmed by a European Parliament declaration in 2005, calling on European Union (EU) and European Economic Area (EEA) member states to increase influenza vaccination in accordance with the WHO's 2010 goal, and extended in a 2009 European Council recommendation to reach 75% vaccination coverage in older age groups by 2015 [17] . Furthermore, the Global Action Plan (GAP) for influenza vaccines was launched by WHO in 2006 with the overarching goal to increase global influenza vaccine production and develop capacity to effectively deliver and administer vaccines in the event of a pandemic through an increased use of seasonal influenza vaccines, in particular in low-and middle income countries [18] . Since the adoption of GAP, global production capacity for seasonal vaccines has increased substantially; from 500 million to 1.5 billion doses in 2015, while the potential for producing pandemic influenza vaccines has increased from 1.5 to 6.4 billion doses in the same time period [19] . Although the GAP project formally ended in 2016, WHO's work to increase access to influenza vaccines in low resource countries is continuing under the Pandemic Influenza Preparedness (PIP) Framework that was endorsed in 2011 [20] .
In the WHO European Region, which consists of 53 member states ( Fig. 1) , data on seasonal influenza vaccine use, recommendations and coverage is limited outside of the EU/EEA member states, where surveys have been conducted regularly beginning from the 2007/2008 influenza season [21] . In order to describe seasonal influenza immunization policies and to assess progress towards improved access to and use of seasonal influenza vaccines in the entire WHO European Region, we implemented a survey among countries outside of the EU/EEA and conducted an analysis of the combined data for the European Region covering the period 2008/2009 to 2014/2015.
Methods
Information on seasonal influenza vaccine recommendations, number of doses distributed and estimates of vaccination coverage by target group was obtained through two different mechanisms. First, data from 29 countries of the EU/EEA was extracted from survey reports published by the Vaccine European New Integrated Collaboration Effort (VENICE) consortium and the European Centre for Disease Prevention and Control (ECDC) [22] [23] [24] . The annual EU/ EEA surveys were conducted using the same methodology. For each survey, a standard questionnaire was developed, piloted and placed on a secure website platform and national experts in each country were requested to complete the on-line questionnaire. The surveys included detailed questions on population groups recommended for influenza vaccination; mechanisms in place to monitor influenza vaccine uptake, including methodology; vaccination coverage by population groups; number of vaccine doses distributed; payment and administration costs for influenza vaccines; health care settings where vaccination is typically provided; communication strategies to promote influenza vaccines; and information on planned policy or operational changes with regard to the national influenza immunization programme. Vaccination coverage was reported by the member states as proportions (data on numerator and denominator were not collected). Throughout the period surveyed, most countries used administrative methods (e.g. patient records or immunization registries) while some countries implemented population surveys (e.g. household, mail, or telephone) to obtain coverage data for certain target groups. A detailed description of the VENICE methodology has been published in the individual survey reports [22] [23] [24] .
Second, in September 2015, the WHO Regional Office for Europe implemented a survey in the remaining 21 WHO European Region member states outside of the EU/EEA, including Croatia, which joined the EU in 2013, covering seven influenza seasons (2008/2009 to 2014/2015) . Data were not requested from Andorra, Monaco, and San Marino. The survey (available in English and Russian) was distributed by email to the focal points for the national immunization programme under the Ministries of Health and included questions on: Quantity of seasonal influenza vaccine doses distributed; existence of national recommendations for vaccination of older people, children, pregnant women (including specification of whether this recommendation applied to certain trimesters and/or of presence underlying chronic illness), persons with chronic illness, residents of long-term care facilities (LTCF), health care workers, and non-health care occupational groups; and estimates of vaccination coverage by target group (including data on number of persons vaccinated and number of persons in target group). Information on which specific chronic medical conditions were included in the national recommendations was not requested in this survey.
Data from the different surveys (EU/EEA and non-EU/EEA) were combined into one dataset using In addition, we obtained information on country total mid-year population and income category (low, lower-middle, upper-middle and high) based on GNI per capita in US$ for the same period from the United Nations, Population Division (2015) [26] and the World Bank [27] , respectively. This information was added to the dataset in order to calculate dose per capita in relation to country economic status.
Descriptive data analysis was performed using Tableau 9.2 (WA, USA) and STATA version 10.0 (StataCorp; College Station, TX, USA).
Results
Of the 50 countries surveyed, 49 provided data for at least one influenza season. Survey responses were provided for all seven years by 45 member states, although data on all variables were not always provided. 
National influenza vaccination policies and vaccine doses available
All but two member states (Azerbaijan and Tajikistan) had a national seasonal influenza vaccination programme in the time period surveyed, although Armenia, Georgia, and the Republic of Moldova did not distribute influenza vaccines in some of the seasons (ranging from one to three seasons).
Forty-five member states provided information on the number of influenza vaccine doses distributed for at least one year. The number of vaccine doses available in member states of the WHO European Region in the last season surveyed (2014/2015) varied considerably; from 0 to 413.3 per 1000 population (n = 36). High income countries (n = 18) distributed a considerably higher number of influenza vaccines doses (median; 139.2 per 1000 population) compared to upper-middle (n = 11) and lower-middle (n = 7) income countries which distributed a median of 25.6 and 6.1 doses per 1000 population respectively in 2014/2015 (Fig. 2) .
The number of vaccine doses distributed in the Region in 2008/2009, compared to 2014/2015, increased from 60 to 68 million doses (data based on countries for which information was available for both seasons; n = 31). This net regional increase was mainly due to increases in five countries; the Russian Federation (10.8 million), Belarus (3.2 million), Kazakhstan (1.2 million), Israel (0.8 million), and Portugal (0.5 million). Half of the countries reported a decline in number of doses distributed (ranging from 5000 to 2.7 million) in the seven year period representing a total of 8.7 million doses. 
Children
Less than half of the member states (21 among 46) had influenza vaccination recommendations for children in 2014/2015. Countries recommending vaccination against influenza for children were mainly in the Eastern part of the region (Fig. 5 ).
Of the 21 member states with a recommendation in 2014/2015, 20 provided information on the age groups targeted. Age groups recommended for influenza vaccination varied; however, most countries had recommendations for all children with some differences in the lower and upper age limit (Fig. 6) .
Coverage data was reported by 13 (62%) of the 21 member states with an influenza vaccination policy for children in 2014/2015, of which ten countries reported vaccination coverage for two separate age-groups. Coverage rates in children in the 2014/2015 season ranged from <1% in a number of countries to almost 80% in Northern Ireland (United Kingdom). The median coverage was 10.9%.
Chronic illnesses
Annual vaccination of persons with chronic diseases was generally recommended throughout the seven-year period by all member states with an influenza vaccination policy, except Turkmenistan, which had no specific recommendation. In two countries, Armenia and Uzbekistan, vaccine recommendations for persons with chronic diseases were not included in the seasonal influenza immunization programme in three In general, countries (data only available for EU/EEA member states) recommended annual influenza vaccination for persons with pulmonary, renal, hepatic, neurologic, and immunosuppressive diseases (including HIV/AIDS). For other chronic disease risk groups; including cardio-vascular disease, diabetes, morbid obesity, persons on long term aspirin use, vaccine recommendations differed by country.
Among the 44 countries with influenza vaccine recommendations for persons with specific chronic illnesses in 2014/2015, 14 (32%) provided information on coverage; most countries reported rates below 40%. Vaccination coverage in this target group ranged from 0.3% in Kyrgyzstan to 86.8% in Georgia. Only four member states (Belarus, Israel, Kazakhstan and the Netherlands) provided data for all seven years. In two of these countries; Belarus and 
Long term care facilities
The majority of countries (89%) recommended seasonal influenza vaccination for persons living at long term care facilities 
Health care workers
All member states with an influenza immunization policy, except one (Denmark), had national recommendations for vaccina- There was a large variation in vaccination uptake in this group, ranging from 2.6% to 99.5%; median 29.5% (2014/2015 data) with few countries reporting a high uptake (>75%) (Albania, Armenia and Belarus). The majority of countries reported coverage rates <40% and in some countries there was an indication of decline, most notably in Romania and Croatia (Fig. 8). 
Occupational groups (non-health care settings)
In 2014/2015, most countries (86%) reported having influenza vaccine recommendations in place for one or more occupational groups, including essential and emergency services (e.g. police, fire and rescue staff), military personnel, border control staff, farm and abattoir workers (poultry and/or swine), veterinary services, social workers, teachers, civil service employees, public transportation employees, airline crew members, and staff working in assisted living facilities, children's homes and boarding schools (n = 42). This presented an increase from 2008/2009 when 60% recommended vaccination for specific occupational groups. Coverage data for these groups was not provided in the surveys.
Discussion
This paper provides the first comprehensive overview of seasonal influenza vaccine availability, policies and coverage in the WHO European Region from the year before the 2009 A(H1N1) pandemic until 2014/2015. The findings highlight major differences across countries regarding availability of seasonal influenza vaccine and coverage in target groups, changes in number of vaccine doses distributed over time in a number of countries, as well as substantial gaps in monitoring of vaccination uptake.
All but two countries in the European Region had national policy recommendations for seasonal influenza vaccination in 2014/2015. Despite an increase in the number of doses distributed in lower-middle income countries since 2008/2009, the quantity of vaccine doses procured remains low in this income group. Yet, in higher income countries there was also significant variability in number of vaccine doses distributed per capita.
Based on data from two-thirds of the member states the overall number of influenza vaccines distributed in the Region increased by 8 million doses between 2008/2009 and 2014/2015. However, this figure concealed large differences, with half of the countries reporting a steady decline in doses distributed. This finding is in keeping with reports by international influenza vaccine manufacturers of a decreasing production for the European market, where the number of vaccine doses distributed fell by 31.5% between 2008 and 2013 [28] . The overall increase in doses reported in this study was mainly due to a substantial increase in quantities of vaccines distributed in a few countries mainly in the Eastern part of the Region, including the Russian Federation, which has its own national production of influenza vaccines [29] .
Annual influenza vaccination for older people, health care workers and persons with chronic diseases was almost universally recommended in the Region, and most countries also had recommendations for residents of LTCFs, and for occupational groups holding key functions in society or persons working in the animal sector, consistent with global recommendations [12, 30] . The number of countries with recommendations for pregnant women had increased considerably between 2008/2009 and 2014/2015. In most countries, the change in policy followed the emergence of the A(H1N1)pdm09 virus in 2009, which was shown to cause severe disease particularly among pregnant women [31] . Less than half of the countries, however, recommended vaccination for children. While countries with this policy generally included infants and young children, only five specifically targeted children 6-59 months old, a priority group among children due to a high disease burden [32] . Influenza vaccine recommendations for children of all ages were particularly widespread in the Eastern part of the Region, where school-closures aimed at controlling seasonal influenza outbreaks are common [33] . Vaccination of school-aged children, who experience high rates of influenza illness and play an important role in transmission of influenza in the community [34, 35] , was also more recently introduced the United Kingdom as a strategy to reduce influenza disease in older individuals and other clinical risk groups [36] .
Despite substantial evidence of severity of influenza among older people, who account for over 90% of deaths due to influenza [37, 38] and a long-standing commitment to increase coverage [16, 17] , vaccination uptake in this risk group remains suboptimal and has even decreased in a number of countries. Only one member state in the Region achieved the goal of vaccinating 75% of older people in 2014/2015. With the exception of residents of LTCFs, a target group that may be relatively easy to reach, the limited data on vaccination rates among other clinical risk groups indicated a low uptake, but with large variations between countries. Many countries also reported poor influenza vaccination uptake among health care workers, which is concerning due to their increased risk of infection compared to non-health care employees and potential role in nosocomial transmission. Furthermore, health care providers that are not vaccinated themselves may be less likely to recommend vaccination to their patients [39] .
Factors influencing vaccination uptake are complex, multidimensional and highly context specific [40] , and can as such not be adequately explored in the type of surveys on which this analysis is based. Nonetheless, in lower-resourced countries in the European Region, low coverage is a result of limited vaccine procurement, suggesting that influenza is not considered a high priority disease. Lack of data on influenza morbidity and mortality, and their associated societal costs, in lower-and middle-income countries may be a contributing factor to this [41, 42] . In other countries of the WHO European Region, low and declining influenza vaccination uptake has been attributed to different factors including lack of confidence in the vaccine (effectiveness and safety), low perceived need for vaccination, lack of recommendation from health care providers, general decline in trust in public health institutions following the 2009 A(H1N1) pandemic, and out-of-pocket costs to receive vaccination [43, 44] . A recent publication reported that influenza vaccination is not provided free of charge to a number of key target groups in several EU/EEA member states [45] . In addition, delivering a national vaccination programme for influenza is challenging due to the diversity of the target groups, which fall outside the well-established childhood immunization programmes.
To effectively address vaccination gaps, it is necessary to understand the key barriers to vaccination at different levels of the health care delivery systems including at the individual, health care provider, and policy level. Recently developed tools, such as the Guide to Tailoring Immunization Programmes (TIP) and the ECDC online tool on influenza vaccination in health care workers, can assist national immunization programmes in analysing the demand and supply-side barriers and enablers for vaccination in order to design evidence-informed interventions to help increase vaccination uptake [46, 47] . Finally, producing country-specific estimates of the clinical and economic burden of influenza could provide important leverage to national influenza vaccination programmes through documenting the magnitude of the disease and its economic and societal impact. In addition to low vaccine uptake, this report also revealed a substantial gap in data on vaccination coverage in the European Region. Efforts to increase vaccination uptake should be accompanied by establishing systems for monitoring vaccination coverage, which is a key indicator of programme performance, and essential for understanding gaps and trends in coverage and assessing the impact of the programme. Nonetheless, influenza vaccination is unique among immunization programmes due to a very heterogeneous target group, who may receive vaccination at different locations (e.g. outpatient clinics, pharmacies, long-term care facilities) and by different health care providers (e.g. paediatricians, obstetricians-gynaecologists, general practitioners), complicating record keeping. Furthermore, denominators for specific target populations, such as persons with chronic underlying diseases, may be difficult and costly to obtain [48] .
Interpretation of influenza vaccination coverage data and vaccine doses presented in this report was limited by a number of factors: First, information on number of doses distributed and vaccination uptake was incomplete and available data may not accurately represent the situation in the WHO European Region. Nonetheless, information on number of distributed doses, available for a larger number of countries, did not suggest that vaccination coverage would be high in countries that did not report data on coverage. Second, we used the total population of each country to estimate access to vaccines per capita. Although a more accurate estimate could have been obtained using target group populations, this information was not available. Third, national vaccination coverage estimates may become available or be updated retrospectively after regional surveys have been completed which would not have been captured in this report. Finally, comparing risk group specific vaccination coverage rates between countries and within countries should be done with some caution as quality of vaccination data may differ and because countries have used different approaches to estimate coverage over time. Both administrative methods and surveys have limitations; the first may lead to inaccurate estimates of coverage if vaccination receipt is not consistently documented throughout the health care system or data on the denominator population are incorrect, while surveys can suffer from non-response and recall bias. However, specific details relating to national methods for calculating vaccination coverage was not available and it could not be assessed whether vaccination coverage rates were over-or underestimated. Moreover, a direct comparison of vaccination uptake for groups such as persons with underlying chronic conditions and health care workers may not be merited as countries include different sub-groups in their recommendations.
Conclusion
Despite widespread national policy recommendations on influenza vaccination, reaching high coverage rates continues to be a challenge in the European Region, as does availability of influenza vaccines in middle-income countries. Low and declining use of seasonal influenza vaccination not only presents a missed opportunity for preventing influenza in vulnerable population groups, but could negatively impact on the global production capacity for pandemic vaccines and on building country capacities for vaccine deployment in the event of a pandemic [19, 49] . An improved understanding of the barriers to vaccination, and the elimination of these, will be critical for increasing uptake and reversing negative trends. Development of national strategies on life-course immunization could be particularly valuable for promoting influenza vaccination due to the diverse patient-and age-groups recommended for vaccination. Nevertheless, since out-of-pocket expenses (even when reimbursable in full or partly) is a well-known barrier to vaccination [44, 50] and places a disproportionate financial burden on patients in lower income groups, provision of free of charge seasonal influenza vaccination to older people and other patient risk groups is an urgent task. A greater focus on improving vaccination coverage among health care workers is also warranted to reduce the risk of influenza infection among staff and their patients and to bolster health care provider's role as vaccination advocates. For lower-resourced member states, global actions to increase access to affordable influenza vaccines should continue.
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